TRIAL DETAIL
Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 06/01/2012 |
Age of Trial (yrs) 12.8 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
Kit inhibitor + Autophagy inhibitor |
|||
Strategy: |
Block KIT + Block Autophagy |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
CTRC 11-71, HSC20120203H |
|||
Sponsor: |
Tyler Curiel, The University of Texas Health Science Center at San Antonio |
|||
Patient Contact: |
Epp Goodwin
210-450-5798
onctrial@idd.org |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
7979 Wurzbach Rd. |
San Antonio |
TX |
78229 |
USA |